Malaysia Nuclear Medicines Market Size, Share, Trends, Growth and Forecast Report 2021-2027

Description

The global Malaysia Nuclear Medicines market garnered revenue around USD 35.70 million in 2020 and projected to reach USD 72.26 million in 2027, with at a compound annual growth rate (CAGR) 10.88% throughout the estimate period from 2021 to 2027. Surge in the number of cancer cases in the Malaysian country and rise in awareness about nuclear medicine boost the growth of the market. However, convenience of treatment with minimally invasive techniques attracts more patients toward the radiopharmaceuticals mode of treatment as compared to chemotherapy. The factors that drive the radiopharmaceuticals industry include rise in incidence of cardiac patients and adoption of clear imaging techniques such as SPECT and PET in Malaysia, with the help of diagnostic equipment. 

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Malaysia Nuclear Medicines market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Malaysia Nuclear Medicines market growth.

The global Malaysia Nuclear Medicines market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

The key players profiled in this report include Cardinal Health, Inc., Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.), GE Healthcare, Ion Beam Applications (Ion Beam Applications, SA), Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.), MERCK KGAA (Sigma Aldrich), Novartis AG (Advanced Accelerator Applications S.A.), Otsuka Holding Co., Ltd. (ABX advanced biochemical compounds GmbH), Siemens Healthcare GmbH, and Taiyo Nippon Sanso Corporation (Mitsubishi Chemical Holdings Corp).

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

By Type

·         Diagnostics

·         Therapeutics

·         Biochemistry Research

By Modality

·         SPECT

o    Technetium 99m

o    Chromium-51

o    Gallium-67

o    Others

·         PET

o    Fluorine 18

o    Gallium-68

o    Others

·         Beta Emitters

·         Alpha Emitters

·         Brachytherapy

·         Others

By Application 

·         Oncology

·         Cardiology

·         Thyroid

·         Neurology

·         Others

By End User 

·         Hospitals & Diagnostic Centers

·         Research Institutes

Regional Analysis and Forecast

Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope: 

 

North America

United States

Canada

 

Europe

Germany

United Kingdom

Italy

France

Rest of EU

 

Asia Pacific

China

India

Japan

Southeast Asia

Rest of APAC

 

Central & South America 

Brazil 

Argentina

Rest of Central & South America 

 

Middle East and Africa

GCC

North Africa

South Africa

TABLE OF CONTENT

Malaysia Nuclear Medicines Market Size, Share & Trends Analysis Report - By Region, And Segment Forecasts, 2020 - 2027

 

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Malaysia Nuclear Medicines Market, By Type

7.1.  Malaysia Nuclear Medicines Market, by Type, 2020-2027

7.1.1.    Diagnostics

7.1.1.1.        Market Revenue and Forecast (2016-2027)

7.1.2.    Therapeutics

7.1.2.1.        Market Revenue and Forecast (2016-2027)

7.1.3.    Biochemistry Research

7.1.3.1.        Market Revenue and Forecast (2016-2027)

Chapter 8.  Global Malaysia Nuclear Medicines Market, By Modality

8.1.  Malaysia Nuclear Medicines Market, by Modality, 2020-2027

8.1.1.    SPECT

8.1.1.1.        Market Revenue and Forecast (2016-2027)

8.1.2.    Technetium 99m

8.1.2.1.        Market Revenue and Forecast (2016-2027)

8.1.3.    Chromium-51

8.1.3.1.        Market Revenue and Forecast (2016-2027)

8.1.4.    Gallium-67

8.1.4.1.        Market Revenue and Forecast (2016-2027)

8.1.5.    Others

8.1.5.1.        Market Revenue and Forecast (2016-2027)

8.1.6.    PET

8.1.6.1.        Market Revenue and Forecast (2016-2027)

8.1.7.    Fluorine 18

8.1.7.1.        Market Revenue and Forecast (2016-2027)

8.1.8.    Gallium-68

8.1.8.1.        Market Revenue and Forecast (2016-2027)

8.1.9.    Others

8.1.9.1.        Market Revenue and Forecast (2016-2027)

8.1.10.  Beta Emitters

8.1.10.1.      Market Revenue and Forecast (2016-2027)

8.1.11.  Alpha Emitters

8.1.11.1.      Market Revenue and Forecast (2016-2027)

8.1.12.  Brachytherapy

8.1.12.1.      Market Revenue and Forecast (2016-2027)

8.1.13.  Others

8.1.13.1.      Market Revenue and Forecast (2016-2027)

Chapter 9.  Global Malaysia Nuclear Medicines Market, By Application

9.1.  Malaysia Nuclear Medicines Market, by Application, 2020-2027

9.1.1.    Oncology

9.1.1.1.        Market Revenue and Forecast (2016-2027)

9.1.2.    Cardiology

9.1.2.1.        Market Revenue and Forecast (2016-2027)

9.1.3.    Thyroid

9.1.3.1.        Market Revenue and Forecast (2016-2027)

9.1.4.    Neurology

9.1.4.1.        Market Revenue and Forecast (2016-2027)

9.1.5.    Others

9.1.5.1.        Market Revenue and Forecast (2016-2027)

Chapter 10.      Global Malaysia Nuclear Medicines Market, By End User

10.1.        Malaysia Nuclear Medicines Market, by End User, 2020-2027

10.1.1.  Hospitals & Diagnostic Centers

10.1.1.1.      Market Revenue and Forecast (2016-2027)

10.1.2.  Research Institutes

10.1.2.1.      Market Revenue and Forecast (2016-2027)

Chapter 11.      Global Malaysia Nuclear Medicines Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, by Type (2016-2027)

11.1.2.  Market Revenue and Forecast, by Modality (2016-2027)

11.1.3.  Market Revenue and Forecast, by Application (2016-2027)

11.1.4.  Market Revenue and Forecast, by End User (2016-2027)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, by Type (2016-2027)

11.1.5.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.1.5.3.      Market Revenue and Forecast, by Application (2016-2027)

11.1.5.4.      Market Revenue and Forecast, by End User (2016-2027)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, by Type (2016-2027)

11.1.6.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.1.6.3.      Market Revenue and Forecast, by Application (2016-2027)

11.1.6.4.      Market Revenue and Forecast, by End User (2016-2027)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, by Type (2016-2027)

11.2.2.  Market Revenue and Forecast, by Modality (2016-2027)

11.2.3.  Market Revenue and Forecast, by Application (2016-2027)

11.2.4.  Market Revenue and Forecast, by End User (2016-2027)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, by Type (2016-2027)

11.2.5.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.2.5.3.      Market Revenue and Forecast, by Application (2016-2027)

11.2.5.4.      Market Revenue and Forecast, by End User (2016-2027)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, by Type(2016-2027)

11.2.6.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.2.6.3.      Market Revenue and Forecast, by Application (2016-2027)

11.2.6.4.      Market Revenue and Forecast, by End User (2016-2027)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, by Type (2016-2027)

11.2.7.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.2.7.3.      Market Revenue and Forecast, by Application (2016-2027)

11.2.7.4.      Market Revenue and Forecast, by End User (2016-2027)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, by Type (2016-2027)

11.2.8.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.2.8.3.      Market Revenue and Forecast, by Application (2016-2027)

11.2.8.4.      Market Revenue and Forecast, by End User (2016-2027)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, by Type (2016-2027)

11.3.2.  Market Revenue and Forecast, by Modality (2016-2027)

11.3.3.  Market Revenue and Forecast, by Application (2016-2027)

11.3.4.  Market Revenue and Forecast, by End User (2016-2027)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, by Type (2016-2027)

11.3.5.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.3.5.3.      Market Revenue and Forecast, by Application (2016-2027)

11.3.5.4.      Market Revenue and Forecast, by End User (2016-2027)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, by Type (2016-2027)

11.3.6.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.3.6.3.      Market Revenue and Forecast, by Application (2016-2027)

11.3.6.4.      Market Revenue and Forecast, by End User (2016-2027)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, by Type (2016-2027)

11.3.7.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.3.7.3.      Market Revenue and Forecast, by Application (2016-2027)

11.3.7.4.      Market Revenue and Forecast, by End User (2016-2027)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, by Type (2016-2027)

11.3.8.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.3.8.3.      Market Revenue and Forecast, by Application (2016-2027)

11.3.8.4.      Market Revenue and Forecast, by End User (2016-2027)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, by Type (2016-2027)

11.4.2.  Market Revenue and Forecast, by Modality (2016-2027)

11.4.3.  Market Revenue and Forecast, by Application (2016-2027)

11.4.4.  Market Revenue and Forecast, by End User (2016-2027)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, by Type (2016-2027)

11.4.5.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.4.5.3.      Market Revenue and Forecast, by Application (2016-2027)

11.4.5.4.      Market Revenue and Forecast, by End User (2016-2027)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, by Type (2016-2027)

11.4.6.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.4.6.3.      Market Revenue and Forecast, by Application (2016-2027)

11.4.6.4.      Market Revenue and Forecast, by End User (2016-2027)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, by Type (2016-2027)

11.4.7.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.4.7.3.      Market Revenue and Forecast, by Application (2016-2027)

11.4.7.4.      Market Revenue and Forecast, by End User (2016-2027)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, by Type (2016-2027)

11.4.8.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.4.8.3.      Market Revenue and Forecast, by Application (2016-2027)

11.4.8.4.      Market Revenue and Forecast, by End User (2016-2027)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, by Type (2016-2027)

11.5.2.  Market Revenue and Forecast, by Modality (2016-2027)

11.5.3.  Market Revenue and Forecast, by Application (2016-2027)

11.5.4.  Market Revenue and Forecast, by End User (2016-2027)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, by Type (2016-2027)

11.5.5.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.5.5.3.      Market Revenue and Forecast, by Application (2016-2027)

11.5.5.4.      Market Revenue and Forecast, by End User (2016-2027)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, by Type (2016-2027)

11.5.6.2.      Market Revenue and Forecast, by Modality (2016-2027)

11.5.6.3.      Market Revenue and Forecast, by Application (2016-2027)

11.5.6.4.      Market Revenue and Forecast, by End User (2016-2027)

Chapter 12.  Company Profiles

12.1.              Cardinal Health, Inc.

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.)

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              GE Healthcare

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              Ion Beam Applications (Ion Beam Applications, SA)

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.)

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              MERCK KGAA (Sigma Aldrich)

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              Novartis AG (Advanced Accelerator Applications S.A.)

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              Otsuka Holding Co., Ltd. (ABX advanced biochemical compounds GmbH)

12.8.1.  Company Overview

12.8.2.  Product Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Siemens Healthcare GmbH

12.9.1.  Company Overview

12.9.2.  Product Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.           Taiyo Nippon Sanso Corporation (Mitsubishi Chemical Holdings Corp).

12.10.1.               Company Overview

12.10.2.               Product Offerings

12.10.3.               Financial Performance

12.10.4.               Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

14.2.              Glossary of Terms

Choose License Type

Checkout Inquiry Sample